Drake, Charles G. http://orcid.org/0000-0001-9610-3677
Pachynski, Russell K.
Subudhi, Sumit K. http://orcid.org/0000-0001-5208-7732
McNeel, Douglas G. http://orcid.org/0000-0003-1471-6723
Antonarakis, Emmanuel S.
Bauer, Todd M.
Lauer, Peter
Brockstedt, Dirk
Patricia, Daniel
Wade, Mark
Zudaire, Enrique
Bandyopadhyay, Nibedita
Parasrampuria, Dolly A.
Girgis, Suzette
Mason, Gary E.
Knoblauch, Roland E.
Stone, Nicole
Infante, Jeffrey R.
Gottardis, Marco M.
Fong, Lawrence http://orcid.org/0000-0002-6428-428X
Funding for this research was provided by:
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Janssen Research and Development
Article History
Received: 14 December 2020
Revised: 6 May 2021
Accepted: 27 May 2021
First Online: 13 July 2021
Compliance with ethical standards
:
: C.G.D. is a current employee of Janssen R&D and reports prior consulting or advisory role for AstraZeneca/MedImmune, Bristol-Myers Squibb, Compugen, Roche/Genentech, Janssen Oncology, Pfizer, Tizona Therapeutics, Inc., Potenza Therapeutics, Merck, Rubius, and Pierre Fabre; travel, accommodation, expenses from Roche/Genentech, AACR, ASCO, Merck Sharp & Dohme, and Pfizer; patents licensed from Johns Hopkins to Bristol-Myers Squibb; stock and other ownership interests in Compugen, Tizona Therapeutics, Inc., Harpoon Therapeutics, and Kleo Pharmaceuticals; and research funding to Johns Hopkins from Bristol-Myers Squibb. R.K.P. reports consulting or advisory role for EMD Serono, Bristol-Myers Squibb, Pfizer/EMD Serono, Sanofi, Jounce Therapeutics, Dendreon, Bayer, and Genomic Health; speakers’ bureau for Dendreon, Merck, Genentech/Roche, AstraZeneca, Sanofi, and Genomic Health; travel, accommodations, expenses from Genentech/Roche, DAVA Oncology; and research funding from Janssen Oncology. S.K.S. reports consulting or advisory role for Amgen, Apricity Health, AstraZeneca, Bayer, Bristol-Myers Squibb, Dava Oncology, Dendreon, Exelixis, Janssen Oncology, and Polaris; travel, accommodations, expenses from AstraZeneca, Bristol-Myers Squibb, Dava Oncology, Dendreon, Parker Institute of Cancer Immunotherapy, and Society for Immunotherapy of Cancer; stock or other ownership in Apricity Health; honoraria from AstraZeneca, Bristol-Myers Squibb, Dava Oncology, Dendreon, Parker Institute of Cancer Immunotherapy, and Society for Immunotherapy of Cancer; and research funding to his institution from AstraZeneca, Bristol-Myers Squibb, and Janssen Oncology. D.G.M. reports consulting or advisory role for Madison Vaccines, Inc.; leadership role for Madison Vaccines, Inc.; travel, accommodations, expenses from Madison Vaccines, Inc., patents licensed from his institution to Madison Vaccines, Inc.; stock and other ownership interests in Madison Vaccines, Inc.; research funding to his institution from Madison Vaccines, Inc. and from Janssen, Bristol-Myers Squibb, Pfizer, Merck, and Novartis. E.S.A. reports consulting or advisory role for Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, and Clovis Oncology; travel, accommodations, expenses from Sanofi, Dendreon, and Medivation; co-inventor of a biomarker technology that has been licensed to Qiagen; honoraria from Sanofi, Dendreon, Medivation, Janssen Biotech, ESSA, Astellas Pharma, Merck, AstraZeneca, and Clovis Oncology; research funding to his institution from Janssen Biotech, Johnson & Johnson, Sanofi, Dendreon, Aragon Pharmaceuticals, Exelixis, Millennium, Genentech, Novartis, Astellas Pharma, Tokai Pharmaceuticals, Merck, AstraZeneca, Clovis Oncology, and Constellation Pharmaceuticals. T.M.B. reports employment with Tennessee Oncology; consulting or advisory role for Guardant Health, Loxo, Pfizer, and Exelixis; consulting or advisory role for his institution for Ignyta, Moderna Therapeutics, and Pfizer; speakers’ bureau for Bayer; travel, accommodations, expenses from Astellas Pharma, AstraZeneca, Celgene, Clovis Oncology, EMD Serono, Genentech, Lilly, Merck, Novartis, Pharmacyclics, and Sysmex; research funding to his institution from Daiichi Sankyo, Medpacto, Inc., Incyte, Mirati Therapeutics, MedImmune, AbbVie, AstraZeneca, Leap Therapeutics, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Pfizer, Genentech/Roche, Deciphera, Merrimack, Immunogen, Millennium, Ignyta, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Moderna Therapeutics, Sanofi, Boehringer Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Loxo, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Onyx, Phosplatin Therapeutics, Foundation Medicine, and ARMO BioSciences. P.L. and Dr. D.B. report former employment with Aduro Biotech. D.P., M.W., E.Z., N.B., D.A.P., S.G., G.E.M., R.E.K., N.S., J.R.I., and M.M.G. report employment with Janssen R&D and stock or other ownership in Johnson & Johnson. L.F. reports consulting or advisory role for Atreca, Nutcracker Therapeutics, Inc., Bolt Biotherapeutics, BioAtla, and TeneoBio and research funding to his institution from Bristol-Myers Squibb, AbbVie, Roche/Genentech, Janssen Oncology, Merck, Bavarian Nordic, and Dendreon.
: The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at ExternalRef removed. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at ExternalRef removed.